490 related articles for article (PubMed ID: 34780850)
1. Treatment of chronic or relapsing COVID-19 in immunodeficiency.
Brown LK; Moran E; Goodman A; Baxendale H; Bermingham W; Buckland M; AbdulKhaliq I; Jarvis H; Hunter M; Karanam S; Patel A; Jenkins M; Robbins A; Khan S; Simpson T; Jolles S; Underwood J; Savic S; Richter A; Shields A; Brown M; Lowe DM
J Allergy Clin Immunol; 2022 Feb; 149(2):557-561.e1. PubMed ID: 34780850
[TBL] [Abstract][Full Text] [Related]
2. Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series.
Rüfenacht S; Gantenbein P; Boggian K; Flury D; Kern L; Dollenmaier G; Kohler P; Albrich WC
Infection; 2022 Jun; 50(3):783-790. PubMed ID: 35426564
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 evolution during treatment of chronic infection.
Kemp SA; Collier DA; Datir RP; Ferreira IATM; Gayed S; Jahun A; Hosmillo M; Rees-Spear C; Mlcochova P; Lumb IU; Roberts DJ; Chandra A; Temperton N; ; ; Sharrocks K; Blane E; Modis Y; Leigh KE; Briggs JAG; van Gils MJ; Smith KGC; Bradley JR; Smith C; Doffinger R; Ceron-Gutierrez L; Barcenas-Morales G; Pollock DD; Goldstein RA; Smielewska A; Skittrall JP; Gouliouris T; Goodfellow IG; Gkrania-Klotsas E; Illingworth CJR; McCoy LE; Gupta RK
Nature; 2021 Apr; 592(7853):277-282. PubMed ID: 33545711
[TBL] [Abstract][Full Text] [Related]
4. Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.
Hopwood AJ; Jordan-Villegas A; Gutierrez LD; Cowart MC; Vega-Montalvo W; Cheung WL; McMahan MJ; Gomez MR; Laham FR
J Pediatric Infect Dis Soc; 2021 May; 10(5):691-694. PubMed ID: 33306130
[TBL] [Abstract][Full Text] [Related]
5. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
6. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
Weinbergerova B; Mayer J; Kabut T; Hrabovsky S; Prochazkova J; Kral Z; Herout V; Pacasova R; Zdrazilova-Dubska L; Husa P; Bednar P; Ruzek D; Lengerova M
Hematol Oncol; 2021 Dec; 39(5):715-720. PubMed ID: 34396566
[No Abstract] [Full Text] [Related]
7. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
[TBL] [Abstract][Full Text] [Related]
8. Early combination therapy of COVID-19 in high-risk patients.
Orth HM; Flasshove C; Berger M; Hattenhauer T; Biederbick KD; Mispelbaum R; Klein U; Stemler J; Fisahn M; Doleschall AD; Baermann BN; Koenigshausen E; Tselikmann O; Killer A; de Angelis C; Gliga S; Stegbauer J; Spuck N; Silling G; Rockstroh JK; Strassburg CP; Brossart P; Panse JP; Jensen BO; Luedde T; Boesecke C; Heine A; Cornely OA; Monin MB
Infection; 2024 Jun; 52(3):877-889. PubMed ID: 38017344
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.
Węcławek-Tompol J; Zakrzewska Z; Gryniewicz-Kwiatkowska O; Pierlejewski F; Bień E; Zaucha-Prażmo A; Zając-Spychała O; Szmydki-Baran A; Mizia-Malarz A; Bal W; Sawicka-Żukowska M; Kruk A; Ociepa T; Raciborska A; Książek A; Szczepański T; Peregud-Pogorzelski J; Krawczuk-Rybak M; Chaber R; Matysiak M; Wachowiak J; Irga-Jaworska N; Młynarski W; Dembowska-Bagińska B; Balwierz W; Matkowska-Kocjan A; Kazanowska B; Styczyński J; Ussowicz M
J Hematol Oncol; 2021 Oct; 14(1):163. PubMed ID: 34635137
[TBL] [Abstract][Full Text] [Related]
10. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
[TBL] [Abstract][Full Text] [Related]
11. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report.
Buckland MS; Galloway JB; Fhogartaigh CN; Meredith L; Provine NM; Bloor S; Ogbe A; Zelek WM; Smielewska A; Yakovleva A; Mann T; Bergamaschi L; Turner L; Mescia F; Toonen EJM; Hackstein CP; Akther HD; Vieira VA; Ceron-Gutierrez L; Periselneris J; Kiani-Alikhan S; Grigoriadou S; Vaghela D; Lear SE; Török ME; Hamilton WL; Stockton J; Quick J; Nelson P; Hunter M; Coulter TI; Devlin L; ; ; Bradley JR; Smith KGC; Ouwehand WH; Estcourt L; Harvala H; Roberts DJ; Wilkinson IB; Screaton N; Loman N; Doffinger R; Lyons PA; Morgan BP; Goodfellow IG; Klenerman P; Lehner PJ; Matheson NJ; Thaventhiran JED
Nat Commun; 2020 Dec; 11(1):6385. PubMed ID: 33318491
[TBL] [Abstract][Full Text] [Related]
12. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
Guan W; Lan W; Zhang J; Zhao S; Ou J; Wu X; Yan Y; Wu J; Zhang Q
Virol Sin; 2020 Dec; 35(6):685-698. PubMed ID: 32997322
[TBL] [Abstract][Full Text] [Related]
13. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
[TBL] [Abstract][Full Text] [Related]
14. Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019.
Martinot M; Jary A; Fafi-Kremer S; Leducq V; Delagreverie H; Garnier M; Pacanowski J; Mékinian A; Pirenne F; Tiberghien P; Calvez V; Humbrecht C; Marcelin AG; Lacombe K
Clin Infect Dis; 2021 Oct; 73(7):e1762-e1765. PubMed ID: 32986807
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Garibaldi BT; Wang K; Robinson ML; Zeger SL; Bandeen-Roche K; Wang MC; Alexander GC; Gupta A; Bollinger R; Xu Y
JAMA Netw Open; 2021 Mar; 4(3):e213071. PubMed ID: 33760094
[TBL] [Abstract][Full Text] [Related]
16. Remdesivir for the treatment of COVID-19.
Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
[TBL] [Abstract][Full Text] [Related]
17. Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.
Ali S; Khalid S; Afridi M; Akhtar S; Khader YS; Akhtar H
JMIR Public Health Surveill; 2021 May; 7(5):e27609. PubMed ID: 34009133
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
[TBL] [Abstract][Full Text] [Related]
20. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
